LOPRESSOR by Novartis is 12. Approved for the treatment of hemodynamically stable adult patients with myocardial infarction, to reduce the risk of cardiovascular mortality, the treatment of hemodynamically stable adult patients with myocardial infarction (mi) to reduce cardiovascular mortality. First approved in 1989.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
LOPRESSOR (metoprolol) is a beta-1 selective adrenergic receptor blocking agent indicated for treatment of hemodynamically stable acute myocardial infarction to reduce cardiovascular mortality. It works by selectively blocking beta-1 adrenergic receptors, thereby reducing heart rate, cardiac output, and blood pressure, with preserved vasodilatory effects at therapeutic doses due to beta-1 selectivity.
Product approaching loss of exclusivity with moderate competitive pressure (score: 30), signaling potential team restructuring and transition focus toward generic optimization.
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg
Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg
Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg
Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg
Working on LOPRESSOR offers limited growth opportunity given its LOE-approaching status and mature market position; roles focus on defensive strategies and generic competition mitigation rather than expansion. This is ideal for professionals seeking stability in a legacy franchise or experience managing product transition and end-of-life commercial strategies.